Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3594-3599

  Evans, Christopher P ^a,b   Elfman, Fred ^a   Parangi, Sareh ^a   Conn, Marion ^a   Cunha, Gerald ^a   Shuman, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; LUCIFERASE; UROKINASE; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; IMMUNOCOMPETENCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BLOOD FLOW;

ANIMALS; GENES, REPORTER; LUCIFERASES; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RATS; RECEPTORS, CELL SURFACE; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030812212     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Liotta, L. A. Tumor invasion and metastases: role of the extracellular matrix. Rhoades Memorial Award Lecture. Cancer Res., 46: 1-7, 1986.
2. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
3. Menashi, S., Lu, H., Soria, C., and Legrand, Y. Endothelial cell proteases: physiological role and regulation. Bailliere's Clin. Hematol., 6: 559-576, 1993.
4. Testa, J. E., and Quigley, J. P. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev., 9: 353-367, 1990.
5. Mignatti, P., and Rifkin, D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73: 161-195, 1993.
6. Gaylis, F. D., Keer, H. N., Wilson, M. J., Kwaan, H. C., Sinha, A. A., and Kozlowski, J. M. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J. Urol., 142: 193-198, 1989.
7. Koeller, A., Kirchheimer, J., Pflueger, H., and Binder, B. R. Tissue plasminogen activator activity in prostatic cancer. Eur. Urol., 10: 389-394, 1984.
8. Achbarou, A., Kaiser, S., Tremblay, G., Ste-Marie, L., Brodt, P., Goltzman, D., and Rabbani, S. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cell in vivo. Cancer Res., 54: 2372-2377, 1994.
9. Jimi, S., Ito, K., Kohno, K., Ono, M., Kuwano, M., Itagaki, Y., and Ishikawa, H. Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem. Biophys. Res. Commun., 211: 476-483, 1995.
10. Peverali, F., Mandriota, S., Ciana, P., Marelli, R., Quax, P., Rifkin, D. B., Della Valle, G., and Mignatti, P. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. J. Cell. Physiol., 161: 1-14, 1994.
11. Ellis, V., Scully, M. F., and Kakkar, V. V. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator potentiation by U937 cells. J. Biol. Chem., 264: 2185-2188, 1989.
12. Cohen, R. L., Xiao-Ping, X., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Shuman, M. A. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood, 78: 479-487, 1991.
13. Petersen, L. C., Lund, L. R., Nielsen, L. S., Dano, K., and Skriver, L. One chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem., 263: 11189-11195, 1988.
14. Appella, E., Robinson, E. A., Ullrich, S. J., Stoppelli, M. P., Corti, A., Cassani, G., and Blasi, F. The receptor-binding sequence of urokinase: a biological function for the growth factor module of proteases. J. Biol. Chem., 262: 4437-4440, 1987.
15. Manchanda, N., and Schwartz, B. S. Single chain urokinase. J. Biol. Chem., 266: 14580-14584, 1991.
16. Ossowski, L., Russo-Payne, H., and Wilson, E. L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res., 51: 274-281, 1991.
17. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35: 611-619, 1983.
18. Kellen, J. A., Mirakian, A., and Kolin, A. Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res., 8: 1373-1376, 1988.
19. Towle, M. J., Lee, A., Maduakor, E. C., Schwartz, C. E., Bridges, A. J., and Littlefield, B. A. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res., 53: 2553-2559, 1993.
20. Cajot, J. F., Bamat, J., Bergonzelli, G. E., Kruithof, E. K. O., Medcalf, R. L., Testuz, J., and Sordat, B. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc. Natl. Acad. Sci. USA, 87: 6939-6943, 1990.
21. Masucci, M. T., Pedersen, N., and Blasi, F. A soluble, ligand-binding mutant of the human urokinase plasminogen activator receptor. J. Biol. Chem., 266: 8655-8658, 1991.
22. Crowley, C. W., Cohen, R. L., Lucas, B. K., Liu, G., Shuman, M. A., and Levinson, A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA, 90: 5021-5025, 1993.
23. Fregene, T., Khanuja, P., Noto, A. C., Gehani, S. K., van Egmont, E. M., Luz, D. A., and Pienta, K. J. Tumor-associated angiogenesis in prostate cancer. Anticancer Res., 13: 2377-2383, 1993.
24. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., and Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143: 401-409, 1993.
25. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potentially inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 52: 5233-5236, 1993.
26. Nguyen, N. M., Lehr, J. E., and Pienta, K. J. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res., 13: 2143-2148, 1993.
27. Pepper, M. S., Vassalli, J. D., Wilks, J. W., Schweiger, L., Orci, L., and Montesano, R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell. Biochem., 55: 419-434, 1994.
28. Belin, D., Vassalli, J. D., Combepine, C., Godeau, F., Nagamine, Y., Reich, E., Kocher, H. P., and Duvoisin, R. M. Cloning, nucleotide sequencing, and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur. J. Biochem., 148: 225-232, 1985.
29. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
30. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Biotechnology, 24: 145-149, 1992.
31. Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostate cancers. Prostate, 9: 261-281, 1986.
32. Hoosein, N. M., Boyd, D. D., Hollas, W. J., Mazar, A., Henkin, J., and Chung, L. W. K. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun., 3: 255-264, 1991.
33. Ichikawa, T., Schalken, J. A., Ichikawa, Y., Steinberg, G. D., Isaacs, J. T. H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. Prostate, 18: 163-172, 1991.
34. Lu, H., Yeh, P., Guitton, J. D., Mabilat, C., Desanlis, F., Maury, I., Legrand, Y., Soria, J., and Soria, C. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett., 356: 56-59, 1994.
35. Min, H. Y., Doyle, L. V., Vitt, C. R., Zandonella, C. L., Stratton-Thomas, J. R., Shuman, M. A., and Rosenberg, S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Caner Res., 56: 2428-2433, 1996.
36. Pepper, M. S., Sappino, A., Stoecklin, R., Montesano, R., Orci, L., and Vassalli, J. Up-regulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol., 122: 673-684, 1993.
37. Peverali, F. A., Mandriota, S. J., Ciana, P., Marelli, R., Quax, P., Rifkin, D. B., Della Valle, G., and Mignatti, P. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. J. Cell. Physiol., 161: 1-14, 1994.
38. Mignatti, P., Mazzieri, R., and Rifkin, D. B. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J. Cell Biol., 113: 1193-1201, 1991.